BioHarvest Sciences Inc. has announced a significant expansion in its capabilities with the successful large-scale production of plant-based exosomes using its proprietary Botanical Synthesis technology. This advancement marks a potential new revenue stream for the company, as it plans to explore opportunities in the health and cosmetic industries. CEO Ilan Sobel highlighted the efficiency of their bioreactors in producing high-value exosomes, which are expected to offer a safer, non-animal-derived alternative to existing options. With the global exosome market projected to grow significantly, BioHarvest's innovation positions it to capitalize on this expanding demand, particularly with plans to introduce a new skincare application within the next 18 to 24 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 265842) on September 10, 2025, and is solely responsible for the information contained therein.
Comments